Korro Bio, Inc. (KRRO) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-42.0%

$9.19

vs $15.85 price

Levered DCF

-$2.54

After debt service

Piotroski score

2 / 9

Weak

Altman Z-score

-1.99

Distress zone

Rating

C-

Overall 1 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
P/E	-0.64×	-4.06×	-0.93×	-0.85×	-51.92×	-42.9×	-28.84×	-22.41×
P/B	1.46×	2.12×	0.44×	-0.5×	8.72×	5.91×	3.23×	-8.9×
P/S	11.77×	149.54×	0×	0×	0×	30.75×	18.68×	0×
EV / EBITDA	-1.17×	-3.72×	0.71×	-3.17×	-32.64×	-38.68×	-18.99×	-25.66×
Gross margin	33.0%	100.0%	0.0%	0.0%	0.0%	95.7%	41.9%	0.0%
Operating margin	-1366.4%	-4047.1%	0.0%	0.0%	0.0%	-74.5%	-71.4%	0.0%
Net margin	-1834.5%	-3680.4%	0.0%	0.0%	0.0%	-71.7%	-64.8%	0.0%
Current ratio	6.9×	8.79×	8.87×	6.56×	11.79×	8.45×	4.19×	11.38×
Debt / equity	0.85×	0.28×	0.2×	-1.69×	0.35×	0.24×	0×	-1.76×
Interest coverage	0×	0×	0×	-499.98×	0×	0×	0×	-178.72×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Return on equity	-228.0%	-52.1%	-47.8%	58.6%	-16.8%	-13.8%	-11.2%	39.7%
Return on invested capital	-83.8%	-43.2%	-41.4%	-86.8%	-20.1%	-11.6%	-12.1%	-46.5%
Return on assets	-103.3%	-36.9%	-36.6%	-78.7%	-11.8%	-10.0%	-8.4%	-43.0%
Free cash flow yield	-105.1%	-23.0%	-100.0%	-119.9%	-3.2%	-4.6%	6.1%	-4.1%
Earnings yield	-155.8%	-24.6%	-108.0%	-118.2%	-1.9%	-2.3%	-3.5%	-4.5%
Enterprise value	$96.9M	$328.7M	-$57.8M	$179.1M	$1.1B	$962.9M	$340.5M	$472.3M
Net debt / EBITDA	-0.26×	0.12×	1.64×	-2.3×	1×	7×	11.16×	-2.32×
Cash conversion cycle (days)	-85	273	0	0	0	-1,269	-16	-1,040